A study shows antibodies from recipients of an mRNA influenza vaccine bind a broader and more diverse set of flu strains over decades, compared with standard vaccine recipients who recognize fewer strains.

Washington University researchers analyzed Modernas investigational mRNA vaccine, mRNA-1010, and found it may elicit broader and more durable immune responses than traditional flu vaccines.

This work is seen as a milestone toward next-generation vaccines, with implications for protecting against rapidly mutating pathogens and strengthening epidemic preparedness.

Modernas vaccine is under FDA review and, if approved, would be the first influenza vaccine to use mRNA technology.

Researchers suggest broader, diverse B cell activation may lessen strain mismatch issues and could lower hospitalizations and deaths during flu seasons.

The findings highlight how mRNA platforms enable quicker updates to vaccines in response to emerging strains, improving resilience to evolving flu seasons.

The work supports the potential for broader, longer-lasting protection from mRNA flu vaccines and their ability to mitigate strain mismatches from annual updates.

The vaccine aims to broaden antibody responses by teaching the body to produce proteins from four influenza strains, reducing vulnerability to drifted strains.

Persistent germinal center responses may broaden the vaccine-induced antibody repertoire, potentially reducing susceptibility to strain mismatches and the need for frequent updates.

In the two-season study with 75 adults, the mRNA vaccine generated higher flu-specific antibody levels and more memory B cells than Fluarix.

Experts note regulatory and public health significance, as FDA decisions and ongoing surveillance will shape efficacy across diverse populations and over the long term.

Experts argue that expanding immune breadth could outpace viral evolution, potentially reducing the need for frequent revaccinations and easing the seasonal flu burden.